Attention-deficit/hyperactivity disorder medications and long-term risk of cardiovascular diseases
Importance Use of attention-deficit/hyperactivity disorder (ADHD) medications has increased
substantially over the past decades. However, the potential risk of cardiovascular disease …
substantially over the past decades. However, the potential risk of cardiovascular disease …
Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic …
Background Methylphenidate is the most frequently prescribed medication for the treatment
of ADHD in children and adolescents in many countries. Although many randomised …
of ADHD in children and adolescents in many countries. Although many randomised …
[HTML][HTML] Treatments in the pipeline for attention-deficit/hyperactivity disorder (ADHD) in adults
GF Veronesi, A Gabellone, A Tomlinson… - Neuroscience & …, 2024 - Elsevier
To provide an overview of treatments in the pipeline for adults with attention-
deficit/hyperactivity disorder (ADHD), we searched https://clinicaltrials. gov/and and …
deficit/hyperactivity disorder (ADHD), we searched https://clinicaltrials. gov/and and …
Long-Term Cardiovascular Effects of Medications for Attention-Deficit/Hyperactivity Disorder—Balancing Benefits and Risks of Treatment
This is a very common question clinicians encounter when discussing the option of starting a
pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD), which includes …
pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD), which includes …
Attention deficit hyperactivity disorder, physical abuse and methylphenidate treatment in children
A growing number of studies show an association between attention deficit hyperactivity
disorder and physical abuse in childhood. We examined temporal associations of physical …
disorder and physical abuse in childhood. We examined temporal associations of physical …
ESCAP endorses the inclusion of methylphenidate in the WHO model lists of essential medicines and in the Union list of critical medicines
European Child & Adolescent Psychiatry pharmacological option for the treatment of
individuals with ADHD, as part of a multimodal approach. Some guidelines, including the …
individuals with ADHD, as part of a multimodal approach. Some guidelines, including the …
Therapeutic Use of Dopamine Enhancers (Stimulants)
A Zuddas, S Carucci - Tasman's Psychiatry, 2023 - Springer
According to international guidelines, dopamine enhancers (stimulants) are recommended
as the first-line pharmacologic treatment for ADHD. Their efficacy on ADHD core and related …
as the first-line pharmacologic treatment for ADHD. Their efficacy on ADHD core and related …
Trigenic COL4A3/COL4A4/COL4A5 pathogenic variants in Alport 12 syndrome: a case report 13
D Rao, R Maas, E Cornelissen, J Wetzels, M Geel - Nephron, 2023 - karger.com
Trigenic COL4A3/COL4A4/COL4A5 pathogenic variants in Alport syndrome: a case report
Page 1 1 1 2 3 4 5 Nephron , DOI: 10.1159/000538587 6 Received: January 26, 2023 7 …
Page 1 1 1 2 3 4 5 Nephron , DOI: 10.1159/000538587 6 Received: January 26, 2023 7 …
[PDF][PDF] Pathogenic Variants in Alport Syndrome: A Case Report
DRRMM Cornelissenb, J Wetzelsa, M van Geelc - 2024 - karger.com
Alport syndrome (AS) is a hereditary kidney disorder of type IV collagen caused by
pathogenic variants in the COL4A3, COL4A4, and COL4A5 genes. Previously several cases …
pathogenic variants in the COL4A3, COL4A4, and COL4A5 genes. Previously several cases …
[PDF][PDF] Doctopic: Primary Research
Background Methylphenidate is the most frequently prescribed medication for the treatment
of ADHD in children and adolescents in many countries. Although many randomised …
of ADHD in children and adolescents in many countries. Although many randomised …